Cost-Effectiveness of Female Human Papillomavirus Vaccination in 179 Countries: A PRIME Modelling Study
This article, published in The Lancet Global Health, reports on a modeling study that assessed the cost-effectiveness and health effects of vaccinating girls against human papillomavirus (HPV) before sexual debut in terms of burden of cervical cancer and mortality. The authors concluded that large between-country disparities exist for HPV vaccination, with countries with the most to gain yet to introduce national HPV vaccination. Support from the GAVI Alliance could help to reduce such disparities, but a substantial burden will remain even after presently projected vaccine introductions.
Author: Jit M, Brisson M, Portnoy A, Hutubessy R
» Visit web page (English)
(Located at www.thelancet.com)
Citation: Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-Effectiveness of Female Human Papillomavirus Vaccination in 179 Countries: A PRIME Modelling Study. The Lancet Global Health. 2014;2(7):e406-e414.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)